Novel Nucleic Acid Sequencing Technology Development (R21)

| Global Health Funding

Sponsor

United States Department of Health and Human Services (HHS)

National Institutes of Health (NIH)

National Human Genome Research Institute (NHGRI)

 

Amount

Upper  400,000 USD

NHGRI intends to commit $500,000 in each of FY 2016-2018 to fund 1-2 new awards per year. The actual number of awards and amount are contingent on NIH appropriations, and the submission of a sufficient number of meritorious applications.

An applicant may request direct costs of up to $200,000 per year and no more than $400,000 for the entire budget period. Because the nature and scope of the proposed research will vary from application to application, it is anticipated that the size and duration of each award will also vary.

The scope of the proposed project should determine the project period. The maximum project period is 3 years.

 

Abstract

This Funding Opportunity Announcement (FOA) solicits R21 grant applications to develop novel technologies that will enable new approaches to DNA and direct RNA sequencing. Applicants may propose to develop novel complete sequencing systems, investigate challenges underlying key novel system components, or propose improvements of at least an order of magnitude improvement to existing systems. Exploration of methods other than those currently in use is highly encouraged. High-risk/high-payoff applications are appropriate to achieve the goals of this FOA.

 

Upcoming Deadlines

14 July 2016 (Confirmed) – Application (Sponsor deadline – required)

All types of non-AIDS applications are due

 

For more information visit

http://pivot.cos.com/funding_opps/160877